Skip to main content

Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma

Agents and Actions volume 30, pages 284–286 (1990)Cite this article

Abstract

In a double blind, randomised, placebo controlled trial in a group of extrinsic asthmatics, we have evaluated the potency and selectivity of ebastine, a new piperidine-type H1-receptor antagonist, against histamine and methacholine-induced bronchoconstriction. The median histamine PC20FEV1 value following placebo was 3.15 mg/ml (0.24–58.84). When compared with placebo, ebastine produced significant protection at 10 mg (median PC20=31.36 mg/ml,p=0.008) and 30 mg (median PC20=42.14 mg/ml,p=0.001) but there appeared to be no significant dose effect. Ebastine also produced a small shift in the methacholine concentration-response curves to the right. We conclude that ebastine is an effective antagonist of histamine-induced bronchoconstriction in the asthmatic airway with evidence of minor blockade of methacholine-induced bronchoconstriction.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. H. G. J. Herxheimer,Antihistamines in bronchial asthma. Br. Med. J.2, 901–905 (1949).

    PubMed  Google Scholar 

  2. J. Vincent, R. Liminana, P. A. Meredith and J. L. Reid,The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br. J. clin. Pharmac.26, 497–501 (1988).

    Google Scholar 

  3. H. Chai, R. S. Farr, L. A. Froehlich, D. A. Mathison, J. A. McLean and R. R. Rosenthal,Standardization of bronchial inhalation challenge procedures. J. Allergy clin. Immunol.56, 323–327 (1975).

    PubMed  Google Scholar 

  4. P. Rafferty and S. T. Holgate,Terfenadine (Seldane) is a potent and selective histamine H 1 receptor antagonist in asthmatic airways. Am. Rev. respir. Dis.135, 181–184 (1987).

    PubMed  Google Scholar 

  5. S. R. Durham, T. H. Lee, O. Cromwell, R. J. Shaw, T. G. Merrett, J. Merrett, P. Cooper and A. B. Kay,Immunologic studies in allergen-induced late-phase asthmatic reactions. J. Allergy clin. Immunol.74, 49–60 (1984).

    PubMed  Google Scholar 

  6. T. H. Lee, M. J. Brown, L. Nagy, R. Causon, M. J. Walport and A. B. Kay,Exercise-induced release of histamine and neutrophil chemotactic factor in atopic asthmatics. J. Allergy clin. Immunol.70, 73–81 (1982).

    PubMed  Google Scholar 

  7. A. Taytard, D. Beaumont, J. C. Pujet, M. Sapene and P. J. Lewis,Treatment of bronchial asthma with terfenadine; a randomized controlled trial. Br. J. clin. Pharmac.24, 743–746 (1987).

    Google Scholar 

Download references

Author information

Affiliations

  1. Immunopharmacology Group, Medicine 1, Level D, Centre Block, Southampton General Hospital, Tremona Road, SO9 4XY, Southampton, Hampshire, UK

    R. Wood-Baker & S. T. Holgate

Authors
  1. R. Wood-Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. T. Holgate
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wood-Baker, R., Holgate, S.T. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents and Actions 30, 284–286 (1990). https://doi.org/10.1007/BF01969062

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01969062

Keywords

  • Placebo
  • Asthma
  • Histamine
  • Placebo Control Trial
  • Methacholine